Lexaria Bioscience Corp. (NASDAQ:LEXX – Get Free Report) insider Vanessa Carle sold 2,567 shares of Lexaria Bioscience stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $4.00, for a total transaction of $10,268.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Lexaria Bioscience Stock Performance
NASDAQ LEXX opened at $3.98 on Friday. The company has a fifty day moving average of $3.11 and a 200 day moving average of $2.90. Lexaria Bioscience Corp. has a 1 year low of $0.80 and a 1 year high of $6.85.
Institutional Trading of Lexaria Bioscience
An institutional investor recently bought a new position in Lexaria Bioscience stock. Cowen AND Company LLC purchased a new position in shares of Lexaria Bioscience Corp. (NASDAQ:LEXX – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 256,327 shares of the company’s stock, valued at approximately $320,000. Cowen AND Company LLC owned approximately 2.46% of Lexaria Bioscience at the end of the most recent quarter. 13.06% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Get Our Latest Report on Lexaria Bioscience
About Lexaria Bioscience
Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.
See Also
- Five stocks we like better than Lexaria Bioscience
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Defense Stocks Soar to New Highs; Higher Highs Are Coming
- What is the Dogs of the Dow Strategy? Overview and Examples
- Generac Raises Guidance: Why Is the Stock Still a Hold?
- Comparing and Trading High PE Ratio Stocks
- Iconic Burger Chain’s Stock Rallies, Defying Market Trends
Receive News & Ratings for Lexaria Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexaria Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.